395 related articles for article (PubMed ID: 20028199)
1. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
7. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
[TBL] [Abstract][Full Text] [Related]
8. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
[TBL] [Abstract][Full Text] [Related]
9. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
11. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease.
Blackhouse G; Assasi N; Xie F; Marshall J; Irvine EJ; Gaebel K; Campbell K; Hopkins R; O'Reilly D; Tarride JE; Goeree R
J Crohns Colitis; 2012 Feb; 6(1):77-85. PubMed ID: 22261531
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
15. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of tumor necrosis factor in Crohn's disease].
Rudakova AV
Eksp Klin Gastroenterol; 2012; (5):83-6. PubMed ID: 23402177
[TBL] [Abstract][Full Text] [Related]
17. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
18. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.
Kaplan GG; Hur C; Korzenik J; Sands BE
Aliment Pharmacol Ther; 2007 Dec; 26(11-12):1509-20. PubMed ID: 17931345
[TBL] [Abstract][Full Text] [Related]
19. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
20. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
Toor K; Druyts E; Jansen JP; Thorlund K
J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
